The combined approach to treatment of patients witn chronic ischemia and diabetic foot syndrome

Poster (download) Mikhail Smagin1, Oleg Shumkov2, Rustam Khapaev3, Mariya Surovtseva4, Olga PoveshСЃhenko5, Vadim Nimaev61Research Institute of Clinical and Experimental Lymphology Branch ICG SB RAS, msa85@inbox.ru2Research Institute of Clinical and Experimental Lymphology Branch ICG SB RAS, shumkov2011@ngs.ru3Research Institute of Clinical and Experimental Lymphology Branch ICG SB RAS, khapaevrs@bionet.nsc.ru4Research Institute of Clinical and Experimental Lymphology Branch ICG SB RAS, mfelde@ngs.ru5Research Institute of Clinical and Experimental Lymphology Branch ICG SB RAS, poveschenkoov@yandex.ru6Research Institute of Clinical and Experimental Lymphology Branch ICG SB RAS, nimaev@gmail.com The data of a clinical study on the use of therapeutic angiogenesis in combination with endovascular revascularization in patients with chronic lower limb ischemia and diabetic foot syndrome have been presented. The positive effect of intramuscular administration of autologous mononuclear cells in addition to restoring arterial blood flow by endovascular revascularization is indicated in the long-term period. This is confirmed by an increase in the level of transcutaneous oxygen tension and local perfusion index. The procedures associated with obtaining autologous mononuclear cells from peripheral blood after mobilization or from the bone marrow, their injection into the gastrocnemius muscle are well tolerated by patients; in this sample of patients there were no adverse events. The developed technology of combined, including surgical treatment of chronic lower limb ischemia in diabetic foot syndrome can be recommended for implementation as part of additional randomized clinical trials in patients with a limb-threatening ischemia and diabetic foot syndrome.

Read More